Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (36,079)	$ (45,857)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,443	1,360
Stock-based compensation	10,307	10,975
Amortization of premiums and accretion of discounts on marketable securities	(4,579)	(2,596)
Amortization of right-of-use assets	848	742
Changes in operating assets and liabilities:
Receivable from collaboration partner	0	(2,112)
Prepaid expenses and other current assets	(2,361)	(977)
Other assets	16	(2,395)
Accounts payable	918	(914)
Accrued liabilities and accrued clinical supply costs	(10,304)	(7,020)
Payable to collaboration partner	7,929	0
Deferred revenue	(15,893)	1,251
Refund liability to collaboration partner	(12,230)	0
Lease liabilities	(1,361)	(1,144)
Other long-term liabilities	0	139
Net cash used in operating activities	(61,346)	(48,548)
Cash flows from investing activities:
Purchase of property and equipment	(533)	(1,025)
Purchase of marketable securities	(196,466)	(120,274)
Maturities of marketable securities	185,234	210,000
Net cash provided by (used in) investing activities	(11,765)	88,701
Cash flows from financing activities:
Proceeds from issuance of common stock upon public offering, net of issuance costs	71,108	0
Proceeds from the exercise of options to purchase common stock	0	1,079
Net cash provided by financing activities	71,108	1,079
Net increase (decrease) in cash, cash equivalents, and restricted cash	(2,003)	41,232
Cash, cash equivalents, and restricted cash at beginning of period	76,101	155,795
Cash, cash equivalents, and restricted cash at end of period	74,098	197,027
Non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued liabilities	$ 31	$ 305